Paclitaxel into the belly for appendix cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a chemotherapy drug (paclitaxel) given directly into the belly for people whose appendix cancer has spread inside the belly and cannot be surgically removed. The goal is to see if this approach is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a type of appendix cancer that has spread in your belly but cannot be removed with surgery.
- Your cancer has not spread outside your belly (like to your liver or lungs).
- You must be well enough to do daily activities (ECOG score 0–2) and have adequate blood counts and liver/kidney function.
- If you or your partner can become pregnant, you must agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
This trial tests a combination of a new drug, ivonescimab, with chemotherapy given directly into the belly for people whose appendix cancer has spread and cannot be removed with surgery. The goal is to see if this treatment can help control the cancer.
This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.
This trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard intravenous chemotherapy improves outcomes for people with stomach or esophageal cancer that has spread to the lining of the abdomen (peritoneal metastasis).
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
Hear when a new Metastatic Appendiceal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.